Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Expert Opinion on Biological Therapy|April 19, 2022
Onasemnogene abeparvovec for the treatment of spinal muscular atrophyHugh J McMillan, Crystal M Proud, Michelle A Farrar, et al.
Muscle & Nerve|July 1, 2021
Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophyElizabeth A Kichula, Crystal M Proud, Michelle A Farrar, et al.
Advances in Therapy|January 16, 2023
Examining Real-World Adherence to Nusinersen for the Treatment of Spinal Muscular Atrophy Using Two Large US Data SourcesBora Youn, Crystal M Proud, Nasha Wang, et al.
The Journal of Clinical Investigation|September 16, 2025
Open-label phase IV trial evaluating nusinersen after onasemnogene abeparvovec in children with spinal muscular atrophyCrystal M Proud, Richard S Finkel, Julie A Parsons, et al.
Journal of Neuromuscular Diseases|November 10, 2025
Onasemnogene abeparvovec gene therapy for treatment of patients with spinal muscular atrophy: Updated real-world practical considerationsCrystal M Proud, Elizabeth A Kichula, Susan E Matesanz, et al.
Neurology. Clinical Practice|October 14, 2024
Spinal Muscular Atrophy Update in Best Practices: Recommendations for Treatment ConsiderationsMary K Schroth, Jennifer Deans, Diana X Bharucha Goebel, et al.
Annals of Clinical and Translational Neurology|September 11, 2023
Combination disease-modifying treatment in spinal muscular atrophy: A proposed classificationCrystal M Proud, Eugenio Mercuri, Richard S Finkel, et al.
Journal of Neuromuscular Diseases|August 29, 2022
Real-world Adherence to Nusinersen in Adults with Spinal Muscular Atrophy in the US: A Multi-site Chart Review StudyLauren Elman, Bora Youn, Crystal M Proud, et al.
Muscle & Nerve|April 25, 2020
The care of patients with Duchenne, Becker, and other muscular dystrophies in the COVID-19 pandemicAravindhan Veerapandiyan, Kathryn R Wagner, Susan Apkon, et al.
Journal of Neuromuscular Diseases|April 12, 2024
Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy for Patients With Duchenne Muscular DystrophyCraig M Zaidman, Natalie L Goedeker, Amal A Aqul, et al.
Pageof 2